NEW YORK (TheStreet) -- CHANGE IN RATINGS
Actavis was upgraded at Leerink Swann to outperform from market perform. $155 price target. Company can exceed near-term earnings expectations, Leerink Swann said.
Air Products was downgraded at Jefferies to hold. Valuation call, as the stock is up 22% since the beginning of May, Jefferies said. $104 price target.
Boston Scientific was upgraded to hold at TheStreet Ratings.
Cabot Oil & Gas was upgraded at Oppenheimer to outperform. Ratings change reflects strong top-line growth, Oppenheimer said. Unparalleled growth in shale-gas industry will generate high FCF, Oppenheimer also said. Price target $100.
Cash America was downgraded at Sterne Agee to underperform from neutral. Price target decreased to $36. There is weakness in U.S. pawn shop lending, and there is already scrutiny on small-bank ACH activity, Sterne Agee said.
Expedia was downgraded at Lazard Capital Markets to neutral from buy. Growth could decelerate in the coming quarters, Lazard Capital Markets said.
Flir Systems was downgraded at J.P. Morgan to underweight from neutral. Price target is $29.50. Shares have reached the price target, downgrading on valuation, J.P. Morgan said.
Francesca's was downgraded to neutral at Wedbush and given a $32 price target. Concerns about a short-term slowdown, Wedbush said. Lackluster mall traffic, contracting margins and a competitive back-to-school environment threaten FRAN's market share, Wedbush also said.
Hormel was upgraded at Credit Suisse to outperform from neutral. $46 price target. Company can outperform its peers in a difficult environment, Credit Suisse said.
KBR was downgraded at William Blair to market perform from outperform. $37 price target. Large projects are being delayed and the company has limited earnings upside potential, William Blair said.
Lazard was upgraded to buy at TheStreet Ratings.
Lear was downgraded at UBS to neutral from buy. Valuation call, as the stock is up 44% year to date, UBS said. $70 price target.
Mettler-Toledo was upgraded at Cantor Fitzgerald to buy. Strong second-quarter beat and pending growth opportunities, said Cantor Fitzgerald. International expansion and margin growth potential drove the bull case and a new $252 price target, Cantor Fitzgerald said.
Noble Energy was downgraded at Bank of America/Merrill Lynch to neutral from buy. $71 price target. Valuation call, as the stock has gained 30% since December, BofA/Merrill Lynch said.
Onyx Pharmaceuticals was downgraded at Robert Baird to neutral from outperform. See limited upside potential to Amgen's bid for the company, Robert Baird said.
Quality Systems was upgraded at Sterne Agee to buy from neutral. Price target was increased to $28. Margins and system sales are going to drive EBITDA and EPS growth, Sterne Agee said.
Range Resources was upgraded at Oppenheimer to outperform and given a new $100 price target. Based on production growth, Oppenheimer said. RRC expects more long-term output growth, and the firm stands as an attractive acquisition target, Oppenheimer said.
Triumph estimates, price target were reduced at Credit Suisse. Shares are now seen reaching $88. Estimates were also cut, as the company is seeing growth headwinds, Credit Suisse said. Outperform rating.
Wesco was upgraded at Wunderlich to buy from hold. Stock is already pricing in negative factors, Wunderlich said.
Whole Foods was downgraded at Cantor Fitzgerald to hold from buy. See limited upside to estimates, Cantor Fitzgerald said. $54 price target.
Woodward was upgraded at Drexel Hamilton to buy from neutral. Price target is $48. The headwinds in the Wind/Renewables unit appears to be over, Drexel Hamilton said.
Stock Comments / EPS Changes
Abbvie estimates, price target were raised at BMO Capital through 2014. Company's pipeline is advancing and guidance appears beatable, BMO Capital said. Market Perform rating and new $48 price target.
Activision estimates, price target were boosted at Credit Suisse. Shares are now seen reaching $23. Estimates were also increased, following the Vivendi buyback. Outperform rating.
Celestica estimates, price target were raised at Citigroup. Shares are now seen reaching $9. Estimates were also increased, given higher realized telecom demand, Citi said. Sell rating.
Healthsouth estimates, price target were boosted at Lazard Capital Markets. Shares are now seen reaching $37. Estimates were also increased, given the company's new guidance. Buy rating.
Lear estimates, price target were increased at Citigroup. Estimates were increased through 2014. Company boosted its guidance, Citi said. Buy rating and new $79 price target.
Patterson-UTI numbers were cut at UBS. Shares are now seen reaching $22. Estimates were also reduced, given difficult industry conditions, UBS said. Neutral rating.
Sprint estimates, price target were lowered at BMO Capital. Estimates were cut through 2014. Network Vision deployment appears to have fallen behind schedule, BMO Capital said. Outperform rating and new $7 price target.
Charles Schwab numbers were raised at Credit Suisse. Shares are now seen reaching $19. Estimates were also increased, following an upbeat management update, Credit Suisse said. Neutral rating.
>To submit a news tip, email: email@example.com.